Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma announces its participation in the Jefferies London Healthcare Conference scheduled for November 18, 2021. Members of the senior management team will present at 3:00 a.m. EST (8:00 a.m. GMT). A pre-recorded webcast will be available on the company's website at the time of the presentation. Zealand Pharma specializes in developing peptide-based medicines, with more than 10 drug candidates in clinical development, two already on the market, and three in late-stage development, alongside partnerships with Boehringer Ingelheim and AstraZeneca.
Zealand Pharma A/S (Nasdaq: ZEAL) announced its financial results for the first nine months of 2021, reporting revenues of DKK 238.6 million (USD 37.1 million), down from DKK 290 million (USD 45.6 million) in 2020. Net operating expenses increased to DKK 906.2 million (USD 141.1 million), resulting in a net operating loss of DKK 762.6 million (USD 118.8 million). Cash and equivalents fell to DKK 1,049 million (USD 163.3 million). Zealand Pharma lowered its 2021 revenue guidance due to lower-than-expected sales of its product Zegalogue, projecting net product revenue of DKK 190 million +/- 10%.
Zealand Pharma has announced a collaboration with DEKA Research to develop a continuous infusion pump for dasiglucagon, targeting congenital hyperinsulinism (CHI). Zealand gains a worldwide, exclusive license for the pump, while DEKA will handle its development and manufacturing. Zealand is responsible for the clinical development and commercialization of the drug-device combination. This partnership aims to enhance treatment options for CHI, a rare pediatric condition.
Zealand Pharma has announced the dosing of the first subject in a Phase 1 clinical trial of ZP8396, an amylin analogue aimed at treating obesity. This single ascending dose trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers. Preclinical data indicates that ZP8396 exhibits strong anti-obesity effects both as a standalone treatment and in combination with GLP-1 analogues. The trial is a significant milestone for Zealand Pharma as it pursues innovative peptide-based medicines for obesity and metabolic conditions.
Zealand Pharma announces a conference call on November 11, 2021, at 4 PM CET (10 AM ET) to discuss its third quarter results. The call will feature key executives including CEO Emmanuel Dulac and CFO Matt Dallas, followed by a Q&A session. The event will be conducted in English, with dial-in numbers available for several countries. Interested participants can access a live audio webcast and slides through Zealand’s investor website. Zealand Pharma focuses on innovative peptide-based medicines and has marketed products like V-Go and Zegalogue.
Zealand Pharma presents promising preclinical data for its amylin analogue ZP8396 and clinical data for BI 456906, a glucagon-GLP1 dual-agonist, at the Obesity Society Annual Meeting. The preclinical results indicate up to 20% weight loss in in vivo models when ZP8396 is combined with semaglutide. Meanwhile, BI 456906 demonstrated clinically relevant body weight reductions of up to 13.7% over 16 weeks in a Phase 1 trial. Both compounds showcase Zealand's innovative pipeline aimed at treating obesity, with further studies planned.
Zealand Pharma (NASDAQ: ZEAL) announced an update regarding its share capital as of September 30, 2021. The company confirmed a total of 43,581,697 shares with a corresponding nominal value of DKK 1 per share, which also represents the total number of voting rights. This announcement follows a previous update on September 10, 2021, regarding the exercise of employee warrants that contributed to the change in share capital.
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions involving its shares conducted by managerial personnel and their associates. This disclosure is a standard regulatory requirement aimed at maintaining transparency in trading activities. Zealand, focused on peptide-based medicines, has two marketed products: V-Go® for diabetes management and Zegalogue® for severe hypoglycemia. The company has advanced several drug candidates into clinical development, showcasing its commitment to innovation in biotechnology.
Zealand Pharma (Nasdaq: ZEAL) announced a share capital increase of DKK 30,748, equating to 30,748 new shares, due to the exercise of employee warrants on September 10, 2021. The exercise prices varied, with DKK 135.30 for 8,089 shares, DKK 100.80 for 14,000 shares, and DKK 138.60 for 8,659 shares, leading to total proceeds of DKK 3,705,779.10. The new shares will be listed on Nasdaq Copenhagen, increasing the total share capital to DKK 43,581,697.
Zealand Pharma (Nasdaq: ZEAL) presented data at the 2021 ESPEN Virtual Congress demonstrating the dose-dependent effects of glepaglutide in treating short bowel syndrome (SBS). The company showcased four posters, including a Poster of Distinction, emphasizing the drug's potential advantages over short-acting GLP-2 analogs. Glepaglutide is currently in Phase 3 clinical trials and has received orphan drug designation from the FDA. The findings reinforce glepaglutide's pharmacokinetic profile and its dosing regimen's efficacy.
